QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Conditions
HER2-positive Metastatic Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California San Francisco Medical Center, San Francisco, California, United States
Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
Smilow Cancer Hospital Care Center, Fairfield, Connecticut, United States
Smilow Cancer Hospital at Glastonbury, Glastonbury, Connecticut, United States
Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut, United States
Smilow Cancer Hospital Care Center, Guilford, Connecticut, United States
Smilow Cancer Hospital at Saint Francis, Hartford, Connecticut, United States
Yale-New Haven Hospital North Haven Medical Center, New Haven, Connecticut, United States
Yale Cancer Center, New Haven, Connecticut, United States
Contact: Principal Investigator (Adriana Kahn, MD)Smilow Cancer Hospital Care Center at Long Ridge, Stamford, Connecticut, United States
Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States
Smilow Cancer Hospital Care Center, Trumbull, Connecticut, United States
Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States
Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States
Georgetown University - Lombardi CCC, Washington D.C., District of Columbia, United States
MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
University of Chicago Medicine Northwest Indiana, Crown Point, Indiana, United States
John's Hopkins Hospital, Baltimore, Maryland, United States
Penn Medicine Princeton Medical Center, Plainsboro, New Jersey, United States
Montefiore Einstein Medical Center, The Bronx, New York, United States
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Angela DeMichele, MD) · BreastCancerClinicalTrials@pennmedicine.upenn.edu · 855-216-0098Contact: Principal Investigator (Angela DeMichele, MD)University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
UPMC Hillman CC, Pittsburgh, Pennsylvania, United States
Smilow Cancer Hospital Care Center, Westerly, Rhode Island, United States
Ben Taub General Hospital, Houston, Texas, United States
MD Anderson Cancer center, Houston, Texas, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
MD Anderson Cancer center, League City, Texas, United States
MD Anderson Cancer Center, Sugar Land, Texas, United States
MD Anderson Cancer center, Woodland, Texas, United States
University of Washington - Fred Hutchinson Cancer Center, Seattle, Washington, United States
Study leads
Angela DeMichele, MD
Principal Investigator
Abramson Cancer Center at Penn Medicine